Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beatrice Setnik

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Pain Medicine (Malden, Mass.)|April 6, 2011
The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodoneBeatrice Setnik, Carl L Roland, Jody M Cleveland, et al.
Current Medical Research and Opinion|October 9, 2018
Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid usersBeatrice Setnik, Kenneth W Sommerville, Glenn C Pixton, et al.
Journal of Clinical Pharmacology|September 19, 2015
Redefining the Recreational Drug User Population in Human Abuse Potential StudiesTalar Hopyan, Pierre Geoffroy, Yuko Hirata, et al.
Pain Medicine (Malden, Mass.)|June 11, 2013
Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid usersBeatrice Setnik, Kenneth Sommerville, Veeraindar Goli, et al.
Postgraduate Medicine|June 18, 2011
Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodoneCarl L Roland, Beatrice Setnik, Jody M Cleveland, et al.
Journal of Opioid Management|May 28, 2013
A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patientsBeatrice Setnik, Carl L Roland, Veeraindar Goli, et al.
Pharmacology, Biochemistry, and Behavior|January 16, 2004
Increased homocysteine levels associated with sex and stress in the learned helplessness model of depressionBeatrice Setnik, Fernanda Gonçalves de Souza, Vania d'Almeida, et al.
Postgraduate Medicine|October 27, 2016
Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic painBeatrice Setnik, Carl L Roland, Glenn C Pixton, et al.
Postgraduate Medicine|September 10, 2011
Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsulesLynn R Webster, Randall Brewer, David Morris, et al.
Clinical Drug Investigation|November 6, 2009
Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover studyJoseph Stauffer, Beatrice Setnik, Marta Sokolowska, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Pain Medicine (Malden, Mass.)|April 6, 2011
The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodoneBeatrice Setnik, Carl L Roland, Jody M Cleveland, et al.
Current Medical Research and Opinion|October 9, 2018
Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid usersBeatrice Setnik, Kenneth W Sommerville, Glenn C Pixton, et al.
Journal of Clinical Pharmacology|September 19, 2015
Redefining the Recreational Drug User Population in Human Abuse Potential StudiesTalar Hopyan, Pierre Geoffroy, Yuko Hirata, et al.
Pain Medicine (Malden, Mass.)|June 11, 2013
Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid usersBeatrice Setnik, Kenneth Sommerville, Veeraindar Goli, et al.
Postgraduate Medicine|June 18, 2011
Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodoneCarl L Roland, Beatrice Setnik, Jody M Cleveland, et al.
Journal of Opioid Management|May 28, 2013
A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patientsBeatrice Setnik, Carl L Roland, Veeraindar Goli, et al.
Pharmacology, Biochemistry, and Behavior|January 16, 2004
Increased homocysteine levels associated with sex and stress in the learned helplessness model of depressionBeatrice Setnik, Fernanda Gonçalves de Souza, Vania d'Almeida, et al.
Postgraduate Medicine|October 27, 2016
Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic painBeatrice Setnik, Carl L Roland, Glenn C Pixton, et al.
Postgraduate Medicine|September 10, 2011
Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsulesLynn R Webster, Randall Brewer, David Morris, et al.
Clinical Drug Investigation|November 6, 2009
Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover studyJoseph Stauffer, Beatrice Setnik, Marta Sokolowska, et al.
Pageof 6